EMAIL THIS PAGE TO A FRIEND

Journal of dental research

Bortezomib Inhibits Osteoclastogenesis and Porphyromonas gingivalis Lipopolysaccharide-induced Alveolar Bone Resorption.


PMID 26130255

Abstract

Healthy bone is maintained by the coordinated activities of osteoblast-mediated bone formation and osteoclast-dependent bone resorption. Pathologic conditions such as hormonal imbalance and inflammation cause increased osteoclastogenesis resulting in osteoporosis, rheumatoid arthritis, and periodontitis. Bortezomib is novel antimyeloma agent that has a direct beneficial effect on bone formation. However, the role of bortezomib in osteoclastogenesis and underlying mechanisms remains to be fully comprehended. In the present study, we show that bortezomib directly inhibited the receptor activator of nuclear factor κB ligand (RANKL)- and lipopolysaccharide-dependent osteoclast differentiation. Interestingly, the bortezomib-mediated inhibition of osteoclastogenesis was transient, since the removal of bortezomib from culture completely restored osteoclast differentiation. Bortezomib impeded the induction and nuclear localization of nuclear factor of activated T cells, cytoplasmic 1 and reduced both macrophage colony-stimulating factor- and RANKL-induced extracellular-signal-regulated kinase (ERK) phosphorylation. In a mouse model of periodontitis, bortezomib prevented alveolar bone erosion induced by Porphyromonas gingivalis lipopolysaccharide. These data not only suggest a previously unappreciated mechanism by which bortezomib regulates bone resorption but also propose novel applications of bortezomib beyond its use as an antimyeloma agent.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA001012
Anti-ARHGAP4 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA001083
Anti-ARHGAP4 antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1410749
Anti-ARHGAP4 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
GW21144 Anti-c-Fos antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
F7799
Anti-c-Fos antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
F137 Anti-c-Fos antibody produced in rabbit, IgG fraction of antiserum, lyophilized powder
HPA018531
Anti-C-FOS antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1306144
ANTI-C-FOS(C-TERMINAL) antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB2100832
Anti-FOS (ab1) antibody produced in rabbit, affinity isolated antibody
SAB2100833
Anti-FOS (ab2) antibody produced in rabbit, affinity isolated antibody
SAB2502116
Anti-FOS antibody produced in goat, affinity isolated antibody, buffered aqueous solution
AV100639
Anti-FOS antibody produced in rabbit, IgG fraction of antiserum
SAB2104185
Anti-FOS antibody produced in rabbit, affinity isolated antibody
SAB4500995
Anti-FOS antibody produced in rabbit, affinity isolated antibody
SAB4500993
Anti-FOS, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4500996
Anti-FOS, C-Terminal antibody produced in rabbit, affinity isolated antibody
WH0000393M1
Monoclonal Anti-ARHGAP4 antibody produced in mouse, clone 3F7, purified immunoglobulin, buffered aqueous solution
SAB5300463
Monoclonal Anti-FOS antibody produced in mouse, clone 2G2, ascites fluid
SAB1402201
Monoclonal Anti-FOS antibody produced in mouse, clone 2D11, purified immunoglobulin, buffered aqueous solution